Association of a complete breast cancer pathologic response with axillary lymph node metastasis via neoadjuvant chemotherapy:Results from the CSBrS-012 study  

作　　者：Le Ma Pin Gao Zhenzhen Liu Dechuang Jiao Rui Ling Jingjing Xiao Yi Zhao Yitong Wang Hongjian Yang Yunjiang Liu Ke Liu Jianguo Zhang Guangyan Li Dahua Mao Yinglei Deng Jianjun He Maimaitiaili Amina Zhigang Yu Wang Fei Yinhua Liu Peifen Fu Minya Yao Jiandong Wang Li Zhu Hongchuan Jiang Zuowei Zhao Xingsong Tian Zhongwei Cao Xinyu Ma Kejin Wu Shaomei Fu Ailin Song Yanwei Wang Jin Feng Zhimin Fan 

机构地区：[1]Department of Breast Surgery,General Surgery Center,The First Hospital of Jilin University,Changchun,Jilin 130021,China [2]Department of Breast Disease,Henan Breast Cancer Center,Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital,Zhengzhou,Henan 450008,China [3]Department of Thyroid,Breast and Vascular Surgery,Xijing Hospital,Fourth Military Medical University,Xi’an,Shaanxi 710032,China [4]Surgical Oncology Department,Shengjing Hospital of China Medical University,Shenyang,Liaoning 110022,China [5]Department of Breast Surgery,The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital),Institute of Basic Medicine and Cancer(IBMC),Chinese Academy of Sciences,Hangzhou,Zhejiang 310022,China [6]Department of Surgery,The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei 052360,China [7]Fourth Department of Breast Surgery,Jilin Cancer Hospital,Changchun,Jilin 130012,China [8]Department of Breast Surgery,The Second Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang 150086,China [9]Department of Breast Surgery,Affiliated Wudang Hospital of Guizhou Medical University,Guiyang,Guizhou 550009,China [10]Department of Breast Surgery,The First Affiliated Hospital of Xi’an Jiaotong University,Xi’an,Shaanxi 710061,China [11]Department of Breast Surgery,The Second Hospital,Cheeloo College of Medicine,Shandong University,Jinan,Shandong 250033,China [12]Breast Disease Center,Peking University First Hospital,Beijing 100034,China [13]Department of Breast Surgery,The First Affiliated Hospital,School of Medicine,Zhejiang University,Hangzhou,Zhejiang 310003,China [14]Department of General Surgery,The First Medical Center,Chinese PLA General Hospital,Beijing 100852,China [15]Department of Breast Surgery,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China [16]Department of Breast Surgery,The Second Affiliated Hospital of Dalian Medical University,Dalian,Liaoning 116023,China [17]Department of Breast and Thyroid Surgery,Shan

出　　处：《Chinese Medical Journal》2024年第11期1369-1371,共3页中华医学杂志（英文版）

基　　金：Beijing Medical Reward Foundation(No.YXJL-2016-0040-0012)

摘　　要：To the Editor:In the last decade,neoadjuvant chemotherapy(NAC)has become a well-accepted treatment option for breast cancer,although few detailed description of NAC in China has yet been reported.[1]A previous study found that among patients with clinically node-negative(cN0)breast cancer,97.7%(432/442)with breast pathologic complete response(bpCR)had ypN0(absence of metastases in the axillary lymph nodes);and 71.6%(882/1232)without bpCR achieved ypN0(P<0.001).As for human epidermal growth factor receptor 2(HER2)positive or triple-negative breast cancer(TNBC)that achieved bpCR.

关 键 词：BREAST PATHOLOGIC CHEMOTHERAPY 

分 类 号：R737.9[医药卫生—肿瘤]